Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 14/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721426 | 0.89 | MLKL (0.40) | — | |
| SCHEMBL900610 | 0.84 | CHRM2 (0.43) | — | |
| SCHEMBL15227170 | 0.82 | MLKL (0.40) | — | |
| SCHEMBL900787 | 0.82 | CHRM3 (0.31) | CHRM3 | |
| SCHEMBL15227236 | 0.74 | HRH3 (0.44) | — | |
| SCHEMBL2719887 | 0.73 | CHRM2 (0.56) | CHRM3 | |
| SCHEMBL900492 | 0.73 | MLKL (0.40) | — | |
| SCHEMBL900448 | 0.73 | IDO1 (0.40) | — | |
| SCHEMBL900132 | 0.73 | CHRM2 (0.49) | — | |
| SCHEMBL900609 | 0.71 | CHRM2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621916-B1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2016-02-10 | — | — | EP | claimed |
| US-9029357-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2015-05-12 | — | — | US | claimed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | claimed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | claimed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | claimed |
| EP-2621916-B1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2016-02-10 | — | — | EP | disclosed |
| US-9029357-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET (FR) | 2015-05-12 | — | — | US | disclosed |
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET SOC CIV (FR) | 2015-01-01 | — | — | US | disclosed |
| US-8802664-B2 | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJECT (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | BIOPROJET (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621916-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041860-A1 | BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS | BIOPROJET (FR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004181-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | CHRM3 96/4885 |
| US-20130231329-A1 | Benzazole Derivatives as Histamine H4 Receptor Ligands | HRH4, HRH3, HRH2 | CHRM3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.